Metrum Research Group
Metrum Research Group is a biomedical modeling and simulation company in Tariffville, Conn, that works in the field of pharmacokinetic/pharmacodynamics modeling.
The company was founded in 2004 by Dr. Marc Gastonguay. In 2022, Gastonguay was succeeded as Chief Executive Officer by Michelle Johnson.[1]
MetrumRG was cited as the first organization in the field of biosimulation to harness the computing power of on-demand elastic cloud computing and move its entire IT infrastructure to the cloud in 2012.[2]
The company is known for contributions to research in several areas:
COVID-19
MetrumRG researcher Matthew Riggs, Ph.D, was part of the team that developed the modeling and simulation framework for the SARS-CoV-2 monoclonal antibodies to advance Eli Lilly & Company's Bamlanivimab into human clinical trials.[3] Eli Lilly was ultimately granted Emergency Use Authorization by the U.S. Food and Drug Administration for Bamlanivimab in November 2020.[4]
Work on the modeling and simulation framework was recognized by the International Society for Pharmacometrics with the Outstanding Research Manuscript Award for 2022.[5]
Diabetes
MetrumRG scientists developed and implemented a model-based strategy to generate evidence of comparative effectiveness between two anti-diabetic medications without the need for a head-to-head clinical trial. The work illustrated a valid approach for indirect drug comparisons, supporting drug development and market access decisions.[6] This work was a collaboration with clinicians and drug development scientists from the Universidade Federal do Rio Grande do Sul and Boehringer Ingelheim.
References
- ↑ Buntz, Brian (October 18, 2022). "Metrum Research Group names Michelle Johnson as its new CEO". Drug Discovery & Development.
- ↑ Davies, Kevin (February 14, 2012). "Two Guys and a Credit Card: Metrum's Amazon Cloud Makeover". Bio-IT World.
- ↑ Riggs, Matthew (2022). "A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial". Clinical Pharmacology & Therapeutics. 2022 Mar;111(3):595-604. doi: 10.1002/cpt.2459. Epub 2021 Nov 17 (3): 595–604. doi:10.1002/cpt.2459. PMC 8653169 Check
|pmc=value (help). PMID 34687040 Check|pmid=value (help). - ↑ "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19". U.S. Food & Drug Administration. November 9, 2020.
- ↑ "Outstanding Research Manuscript Award". International Society of Pharmacometrics.
- ↑ Gross, J. L.; Rogers, J.; Polhamus, D.; Gillespie, W.; Friedrich, C.; Gong, Y.; Monz, B. U.; Patel, S.; Staab, A.; Retlich, S. (March 5, 2013). "A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus". BMJ Open. 3 (3): e001844. doi:10.1136/bmjopen-2012-001844. PMC 3612798. PMID 23468467.
This article "Metrum Research Group" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Metrum Research Group. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
